WO2018062765A1 - Anti-stress composition containing magnolol - Google Patents

Anti-stress composition containing magnolol Download PDF

Info

Publication number
WO2018062765A1
WO2018062765A1 PCT/KR2017/010388 KR2017010388W WO2018062765A1 WO 2018062765 A1 WO2018062765 A1 WO 2018062765A1 KR 2017010388 W KR2017010388 W KR 2017010388W WO 2018062765 A1 WO2018062765 A1 WO 2018062765A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
acid
stress
magnolol
present
Prior art date
Application number
PCT/KR2017/010388
Other languages
French (fr)
Korean (ko)
Inventor
김주원
최민식
홍용덕
조시영
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2018062765A1 publication Critical patent/WO2018062765A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Definitions

  • the present specification describes an antistress composition
  • an antistress composition comprising magnolol, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof or a solvate thereof.
  • Stress which indicates maladjustment of the human body due to external stimuli or environmental changes, may cause hyperactivation of the sympathetic nervous system, resulting in transient or persistent psychological and physical reactions. Modern people are exposed to various stress sources, which are closely related to changes in various mental and physical conditions, which raises interest in resistance to stress.
  • Antidepressant stress therapeutic agents using synthetic compounds can cause side effects and human toxicity, and there is a need for substances that exhibit antistress effects using natural products as cosmetics or foods, not as drugs.
  • the problem to be solved by the present invention is to provide a composition exhibiting an effect of improving the stress resistance.
  • the problem to be solved by the present invention is to provide a composition that exhibits the effect of improving stress resistance without human toxicity using natural products.
  • the problem to be solved by the present invention is to provide a composition excellent in resistance to glucocorticoid hormone-induced stress.
  • the problem to be solved by the present invention is to provide a composition for alleviating or improving physical symptoms caused by stress.
  • the problem to be solved by the present invention is to provide a composition for alleviating or improving the psychological symptoms caused by stress.
  • the present invention provides an antistress composition
  • an antistress composition comprising magnolol, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
  • the present invention can exhibit a stress resistance improving effect.
  • the present invention can exhibit the effect of improving stress resistance without natural toxicity using natural products.
  • the present invention may be excellent resistance to glucocorticoid hormone-induced stress.
  • the present invention can alleviate or ameliorate physical symptoms caused by stress.
  • the present invention may alleviate or ameliorate psychological symptoms caused by stress.
  • 1 is a graph confirming the inhibitory effect of glucocorticoid-induced cell death of magnolol.
  • pharmaceutically acceptable means the approval of a government or equivalent regulatory body to use in animals, more specifically in humans, by avoiding significant toxic effects when used in conventional medicinal dosages. It can be received or approved, or listed in a pharmacopoeia or recognized as another general pharmacopeia.
  • salt means a salt according to one aspect of the invention that is pharmaceutically or cosmetically acceptable and has the desired pharmacological activity of the parent compound.
  • the salt is formed from (1) an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like; Or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-ch
  • hydrate refers to a compound to which water is bound, and is a broad concept including an inclusion compound having no chemical bonding force between water and the compound.
  • solvate means a higher order compound produced between molecules or ions of a solute and molecules or ions of a solvent.
  • an antistress composition comprising magnolol, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
  • the magnolol is a small molecule polyphenol, a compound having a structure represented by the following formula.
  • the magnolol is known as a material that exhibits anti-inflammatory and antibacterial properties, but the present inventors have found that magnolol has an effect of improving stress resistance. Therefore, the composition according to the present embodiment may exhibit excellent effects as a composition for antistress.
  • the composition is resistant to glucocorticoid-based hormone-induced stress.
  • the composition may inhibit cell death induced by glucocorticoid hormone. Through the inhibition of apoptosis induced by the glucocorticoid-based hormones may exhibit an alleviation or improvement of psychological or physical symptoms.
  • the glucocorticoid hormone may include one or more selected from cortisol, cortisone, and corticosterone.
  • the composition may relieve or ameliorate physical symptoms caused by stress.
  • physical symptoms caused by the stress include irritable colitis, indigestion, gastritis, stomach cramps, gastroduodenal ulcers, digestive symptoms such as constipation, nervous system symptoms such as migraine, urinary symptoms such as erectile dysfunction, insensitivity, hypertension, angina, etc. Cardiovascular symptoms, hair loss, and skin symptoms such as hives. Such symptoms can develop into a disease due to constant stress.
  • the composition may relieve or ameliorate the psychological symptoms caused by stress.
  • Examples of the psychological symptoms may include depression, anxiety disorder, insomnia, and nervousness.
  • the composition may be a cosmetic composition.
  • the cosmetic composition according to the embodiment of the present invention may include 0.0001% by weight to 99% by weight, for example 0.01% by weight to 60% by weight, based on the total weight of the composition, but is not limited thereto.
  • Cosmetic compositions according to embodiments of the present invention may be formulated containing a cosmetically or dermatologically acceptable medium or base. It is any formulation suitable for topical application, in the form of suspensions, microemulsions, microcapsules, microgranules or ionic (liposomal) and nonionic vesicle dispersants or creams, skins, lotions, powders, ointments, sprays or concealers. It may be provided in the form of a stick. It may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.
  • the cosmetic composition according to the embodiments of the present invention may be a powder, a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant.
  • ionic or nonionic emulsifiers fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics It may contain adjuvants conventionally used in the cosmetic or dermatological fields, such as any other ingredients used. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological arts.
  • the cosmetic composition according to the embodiments of the present invention may further contain a skin absorption promoting substance to increase the skin improving effect.
  • compositions according to embodiments of the present invention may be provided in various forms of food additives or functional foods containing the active ingredient. It can be processed into fermented milk, cheese, yogurt, juice, probiotic and health food, including the active ingredient, and can be used in the form of various other food additives.
  • composition according to the embodiments of the present invention may be a composition for health food.
  • the health food composition according to the embodiment of the present invention may include 0.0001% by weight to 99% by weight, for example, 0.01% by weight to 60% by weight, based on the total weight of the composition, but is not limited thereto.
  • the health food composition may be formulated as pills, capsules, tablets, granules, caramels or drinks. In other embodiments, it may be processed in the form of a liquid, powder, granules, tablets or tea bags and the like.
  • composition may be administered by various methods, such as simple drinking, injection, spray or squeeze.
  • the composition may contain other ingredients and the like that can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention.
  • it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included.
  • ingredients may be suitably selected and formulated by those skilled in the art according to the dosage form or purpose of use, and the amount thereof may be selected within a range that does not impair the object and effect of the present invention.
  • the amount of the components added may be 0.01 wt% to 5 wt%, for example, 0.01 wt% to 3 wt%, based on the total weight of the composition, but is not limited thereto.
  • Test Example 1 Glucocorticoid-induced cell death inhibitory effect
  • PC12 neurocytoma cell; KCLB21721, Korea Cell Line Bank
  • PC12 neurocytoma cell; KCLB21721, Korea Cell Line Bank
  • Culture medium was prepared using RPMI 1640 (10% serum (FBS, Gibco), 100 U / ml penicillin (Gibco) and 100 ⁇ g / ml streptomycin (Gibco). Gibco BRL, Grand Island, NY, USA)) media.
  • the stress hormone corticosterone corticosterone, sigma, MA
  • magnolol has an excellent effect of inhibiting corticosteroid induced cell death, a typical stress-related glucocorticoid hormone.
  • composition shown in the following table was prepared in the conventional method for the flexible cosmetic.
  • a hair lotion is prepared according to a conventional method with the composition described in the table below.
  • a shampoo composition was prepared according to a conventional method with the compositions described in the table below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)

Abstract

The present specification describes an anti-stress composition containing magnolol, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof or a solvate thereof as an active ingredient. The composition may alleviate or improve stress-induced physical and psychological symptoms.

Description

마그놀롤을 포함하는 항스트레스 조성물Antistress Compositions Containing Magnolol
본 명세서는 마그놀롤, 이의 약학적 또는 화장품학적으로 허용 가능한 염, 이의 수화물 또는 이의 용매화물을 포함하는 항스트레스 조성물에 관하여 기술한다.The present specification describes an antistress composition comprising magnolol, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof or a solvate thereof.
외부 자극 또는 환경 변화 등으로 인한 인체의 부적응을 나타내는 스트레스는 교감신경계의 과활성화를 야기하여 일시적 또는 지속적인 심리 및 신체적 반응을 나타낼 수 있다. 현대인들은 다양한 스트레스원에 노출되며 이는 다양한 심신 상태의 변화과 밀접한 관련을 가지기 때문에 스트레스에 대한 저항성에 대한 관심이 높아지고 있다.Stress, which indicates maladjustment of the human body due to external stimuli or environmental changes, may cause hyperactivation of the sympathetic nervous system, resulting in transient or persistent psychological and physical reactions. Modern people are exposed to various stress sources, which are closely related to changes in various mental and physical conditions, which raises interest in resistance to stress.
합성 화합물을 이용한 우울증 스트레스 치료제는 부작용이나 인체 독성을 유발할 수 있으며, 약물로서가 아닌 화장료나 식품으로서 천연물을 이용한 항스트레스 효과를 나타내는 물질에 대한 요구가 존재한다.Antidepressant stress therapeutic agents using synthetic compounds can cause side effects and human toxicity, and there is a need for substances that exhibit antistress effects using natural products as cosmetics or foods, not as drugs.
일 관점에서, 본 발명이 해결하고자 하는 과제는 스트레스 저항성 개선 효과를 나타내는 조성물을 제공하는 것이다.In one aspect, the problem to be solved by the present invention is to provide a composition exhibiting an effect of improving the stress resistance.
다른 관점에서, 본 발명이 해결하고자 하는 과제는 천연물을 사용하여 인체 독성 없이 스트레스 저항성 개선효과를 나타내는 조성물을 제공하는 것이다.In another aspect, the problem to be solved by the present invention is to provide a composition that exhibits the effect of improving stress resistance without human toxicity using natural products.
또 다른 관점에서, 본 발명이 해결하고자 하는 과제는 글루코코르티코이드계 호르몬 유도성 스트레스에 대한 저항성이 우수한 조성물을 제공하는 것이다.In another aspect, the problem to be solved by the present invention is to provide a composition excellent in resistance to glucocorticoid hormone-induced stress.
또 다른 관점에서, 본 발명이 해결하고자 하는 과제는 스트레스로 인한 신체적 증상을 완화 또는 개선시키는 조성물을 제공하는 것이다.In another aspect, the problem to be solved by the present invention is to provide a composition for alleviating or improving physical symptoms caused by stress.
또 다른 관점에서, 본 발명이 해결하고자 하는 과제는 스트레스로 인한 심리적 증상을 완화 또는 개선시키는 조성물을 제공하는 것이다.In another aspect, the problem to be solved by the present invention is to provide a composition for alleviating or improving the psychological symptoms caused by stress.
일 관점에서, 본 발명은 마그놀롤(magnolol), 이의 약학적 또는 화장품학적으로 허용 가능한 염, 이의 수화물 또는 이의 용매화물을 유효성분으로 포함하는 항스트레스 조성물을 제공한다.In one aspect, the present invention provides an antistress composition comprising magnolol, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
일 관점에서, 본 발명은 스트레스 저항성 개선 효과를 나타낼 수 있다.In one aspect, the present invention can exhibit a stress resistance improving effect.
다른 관점에서, 본 발명은 천연물을 사용하여 인체 독성 없이 스트레스 저항성 개선효과를 나타낼 수 있다.In another aspect, the present invention can exhibit the effect of improving stress resistance without natural toxicity using natural products.
또 다른 관점에서, 본 발명은 글루코코르티코이드계 호르몬 유도성 스트레스에 대한 저항성이 우수할 수 있다.In another aspect, the present invention may be excellent resistance to glucocorticoid hormone-induced stress.
또 다른 관점에서, 본 발명은 스트레스로 인한 신체적 증상을 완화 또는 개선시킬 수 있다.In another aspect, the present invention can alleviate or ameliorate physical symptoms caused by stress.
또 다른 관점에서, 본 발명은 스트레스로 인한 심리적 증상을 완화 또는 개선시킬 수 있다.In another aspect, the present invention may alleviate or ameliorate psychological symptoms caused by stress.
도 1은 마그놀롤의 글루코코르티코이드 유도성 세포 사멸 억제 효과를 확인한 그래프이다.1 is a graph confirming the inhibitory effect of glucocorticoid-induced cell death of magnolol.
이하, 첨부한 도면들을 참조하여, 본 출원의 실시예들을 보다 상세하게 설명하고자 한다. 그러나 본 출원에 개시된 기술은 여기서 설명되는 실시예들에 한정되지 않고 다른 형태로 구체화될 수도 있다. 단지, 여기서 소개되는 실시예들은 개시된 내용이 철저하고 완전해질 수 있도록 그리고 당업자에게 본 출원의 사상이 충분히 전달될 수 있도록 하기 위해 제공되는 것이다. 도면에서 각 구성요소를 명확하게 표현하기 위하여 구성요소의 폭이나 두께 등의 크기를 다소 확대하여 나타내었다. 또한, 설명의 편의를 위하여 구성요소의 일부만을 도시하기도 하였으나, 당업자라면 구성요소의 나머지 부분에 대하여도 용이하게 파악할 수 있을 것이다. 또한, 해당 분야에서 통상의 지식을 가진 자라면 본 출원의 기술적 사상을 벗어나지 않는 범위 내에서 본 출원의 사상을 다양한 다른 형태로 구현할 수 있을 것이다.Hereinafter, with reference to the accompanying drawings, it will be described embodiments of the present application in more detail. However, the technology disclosed in the present application is not limited to the embodiments described herein and may be embodied in other forms. It is merely to be understood that the embodiments introduced herein are provided so that the disclosure can be made thorough and complete, and that the spirit of the present application can be fully conveyed to those skilled in the art. In order to clearly express each component in the drawings, the size, such as the width or thickness of the component, is shown to be somewhat enlarged. In addition, although only a part of the components are shown for convenience of description, those skilled in the art will be able to easily understand the rest of the components. In addition, one of ordinary skill in the art may implement the spirit of the present application in various other forms without departing from the technical spirit of the present application.
본 명세서에서 "약학적으로 허용 가능"이란 통상의 의약적 복용량(medicinal dosage)으로 이용할 때 상당한 독성 효과를 피함으로써, 동물, 더 구체적으로는 인간에게 사용할 수 있다는 정부 또는 이에 준하는 규제 기구의 승인을 받을 수 있거나 승인 받거나, 또는 약전에 열거되거나 기타 일반적인 약전으로 인지되는 것을 의미한다.As used herein, "pharmaceutically acceptable" means the approval of a government or equivalent regulatory body to use in animals, more specifically in humans, by avoiding significant toxic effects when used in conventional medicinal dosages. It can be received or approved, or listed in a pharmacopoeia or recognized as another general pharmacopeia.
본 명세서에서 "약학적 또는 화장품학적으로 허용 가능한 염"은 약학적 또는 화장품학적으로 허용 가능하고 모 화합물(parent compound)의 바람직한 약리 활성을 갖는 본 발명의 일측면에 따른 염을 의미한다. 상기 염은 (1) 염산, 브롬화수소산, 황산, 질산, 인산 등과 같은 무기산으로 형성되거나; 또는 아세트산, 프로파이온산, 헥사노산, 시클로펜테인프로피온산, 글라이콜산, 피루브산, 락트산, 말론산, 숙신산, 말산, 말레산, 푸마르산, 타르타르산, 시트르산, 벤조산, 3-(4-히드록시벤조일) 벤조산, 신남산, 만델산, 메테인설폰산, 에테인설폰산, 1,2-에테인-디설폰산, 2-히드록시에테인설폰산, 벤젠설폰산, 4-클로로벤젠설폰산, 2-나프탈렌설폰산, 4-톨루엔설폰산, 캄퍼설폰산, 4-메틸바이시클로 [2,2,2]-oct-2-엔-1-카르복실산, 글루코헵톤산, 3-페닐프로파이온산, 트리메틸아세트산, tert-부틸아세트산, 라우릴 황산, 글루콘산, 글루탐산, 히드록시나프토산, 살리실산, 스테아르산, 뮤콘산과 같은 유기산으로 형성되는 산 부가염(acid addition salt); 또는 (2) 모 화합물에 존재하는 산성 프로톤이 치환될 때 형성되는 염을 포함할 수 있다.As used herein, "pharmaceutically or cosmetically acceptable salt" means a salt according to one aspect of the invention that is pharmaceutically or cosmetically acceptable and has the desired pharmacological activity of the parent compound. The salt is formed from (1) an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like; Or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo [2,2,2] -oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert Acid addition salts formed with organic acids such as butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid; Or (2) salts formed when the acidic protons present in the parent compound are substituted.
본 명세서에서 "수화물(hydrate)"은 물이 결합되어 있는 화합물을 의미하며, 물과 화합물 사이에 화학적인 결합력이 없는 내포 화합물을 포함하는 광범위한 개념이다.As used herein, "hydrate" refers to a compound to which water is bound, and is a broad concept including an inclusion compound having no chemical bonding force between water and the compound.
본 명세서에서 "용매화물"은 용질의 분자나 이온과 용매의 분자나 이온 사이에 생긴 고차의 화합물을 의미한다.As used herein, the term "solvate" means a higher order compound produced between molecules or ions of a solute and molecules or ions of a solvent.
본 발명 일 실시예에 따르면, 마그놀롤(magnolol), 이의 약학적 또는 화장품학적으로 허용 가능한 염, 이의 수화물 또는 이의 용매화물을 유효성분으로 포함하는 항스트레스 조성물을 제공할 수 있다.According to one embodiment of the present invention, it is possible to provide an antistress composition comprising magnolol, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
본 실시예에서, 상기 마그놀롤은 소분자 폴리페놀로, 하기 화학식으로 표시되는 구조를 가지는 화합물이다. 상기 마그놀롤은 항염, 항균을 나타내는 물질로서 알려져 있으나, 본 발명자들은 마그놀롤이 스트레스 저항성 개선 효과를 나타내는 점을 발견하였다. 따라서 본 실시예에 따른 조성물은 항스트레스용 조성물로서 우수한 효과를 나타낼 수 있다.In this embodiment, the magnolol is a small molecule polyphenol, a compound having a structure represented by the following formula. The magnolol is known as a material that exhibits anti-inflammatory and antibacterial properties, but the present inventors have found that magnolol has an effect of improving stress resistance. Therefore, the composition according to the present embodiment may exhibit excellent effects as a composition for antistress.
<화학식><Formula>
Figure PCTKR2017010388-appb-I000001
Figure PCTKR2017010388-appb-I000001
상기 조성물은 글루코코르티코이드(glucocorticoid)계 호르몬 유도성 스트레스에 저항성을 가진다. 일예에서, 상기 조성물은 글루코코르티코이드(glucocorticoid)계 호르몬으로 유도되는 세포 사멸을 억제할 수 있다. 상기 글루코코르티코이드계 호르몬으로 유도되는 세포 사멸 억제를 통하여 심리적 또는 신체적 증상의 완화 또는 개선 효과를 나타낼 수 있다. 상기 글루코코르티코이드(glucocorticoid)계 호르몬은 코티솔(cortisol), 코티손(cortisone) 및 코르티코스테론(corticosterone) 중에서 선택되는 1종 이상을 포함할 수 있다.The composition is resistant to glucocorticoid-based hormone-induced stress. In one embodiment, the composition may inhibit cell death induced by glucocorticoid hormone. Through the inhibition of apoptosis induced by the glucocorticoid-based hormones may exhibit an alleviation or improvement of psychological or physical symptoms. The glucocorticoid hormone may include one or more selected from cortisol, cortisone, and corticosterone.
상기 조성물은 스트레스로 인하여 유발되는 신체 증상을 완화 또는 개선시킬 수 있다. 상기 스트레스로 유발되는 신체 증상의 예로는 과민성 대장염, 소화불량, 위염, 위경련, 위십이지장궤양, 변비 등의 소화기 증상, 편두통과 같은 신경계 증상, 발기부전, 불감증과 같은 비뇨기 증상, 고혈압, 협심증 등과 같은 심혈관 증상, 탈모, 두드러기 등의 피부 증상 등을 들 수 있다. 이와 같은 증상은 지속적인 스트레스에 의하여 질환으로 발전할 수 있다.The composition may relieve or ameliorate physical symptoms caused by stress. Examples of physical symptoms caused by the stress include irritable colitis, indigestion, gastritis, stomach cramps, gastroduodenal ulcers, digestive symptoms such as constipation, nervous system symptoms such as migraine, urinary symptoms such as erectile dysfunction, insensitivity, hypertension, angina, etc. Cardiovascular symptoms, hair loss, and skin symptoms such as hives. Such symptoms can develop into a disease due to constant stress.
상기 조성물은 스트레스로 인하여 유발되는 심리적 증상을 완화 또는 개선시킬 수 있다. 상기 심리적 증상의 예로는 우울증, 불안장애, 불면증, 신경과민 등을 들 수 있다.The composition may relieve or ameliorate the psychological symptoms caused by stress. Examples of the psychological symptoms may include depression, anxiety disorder, insomnia, and nervousness.
일 실시예에 있어서, 상기 조성물은 화장료 조성물일 수 있다.In one embodiment, the composition may be a cosmetic composition.
본 발명의 실시예에 따른 화장료 조성물은 상기 유효성분을 조성물 총 중량에 대하여 0.0001중량% 내지 99중량%, 예를 들어 0.01 중량% 내지 60중량%로 포함할 수 있으나, 이에 제한되지 않는다.The cosmetic composition according to the embodiment of the present invention may include 0.0001% by weight to 99% by weight, for example 0.01% by weight to 60% by weight, based on the total weight of the composition, but is not limited thereto.
본 발명의 실시예에 따른 화장료 조성물은 화장품학 또는 피부과학적으로 허용가능한 매질 또는 기제를 함유하여 제형화될 수 있다. 이는 국소적용에 적합한 모든 제형으로서, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀) 및 비이온형의 소낭 분산제의 형태로, 또는 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 또한 포말(foam)의 형태로 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 사용될 수 있다. 이들 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.Cosmetic compositions according to embodiments of the present invention may be formulated containing a cosmetically or dermatologically acceptable medium or base. It is any formulation suitable for topical application, in the form of suspensions, microemulsions, microcapsules, microgranules or ionic (liposomal) and nonionic vesicle dispersants or creams, skins, lotions, powders, ointments, sprays or concealers. It may be provided in the form of a stick. It may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.
또한, 본 발명의 실시예들에 따른 화장료 조성물은 분체, 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 상기 보조제는 화장품학 또는 피부과학 분야에서 일반적으로 사용되는 양으로 도입된다. 본 발명의 실시예들에 따른 화장료 조성물은 피부 개선 효과를 증가시키기 위하여 피부 흡수 촉진 물질을 더 함유할 수 있다. In addition, the cosmetic composition according to the embodiments of the present invention may be a powder, a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant. Commonly used in water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics It may contain adjuvants conventionally used in the cosmetic or dermatological fields, such as any other ingredients used. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological arts. The cosmetic composition according to the embodiments of the present invention may further contain a skin absorption promoting substance to increase the skin improving effect.
본 발명 실시예들에 따른 조성물은 상기 유효성분을 포함하는 다양한 형태의 식품 첨가제 또는 기능성 식품으로 제공될 수 있다. 상기 유효성분을 포함하는 발효유, 치즈, 요구르트, 주스, 생균제제 및 건강식품 등으로 가공될 수 있으며, 그 외 다양한 식품 첨가제의 형태로 사용될 수 있다.Compositions according to embodiments of the present invention may be provided in various forms of food additives or functional foods containing the active ingredient. It can be processed into fermented milk, cheese, yogurt, juice, probiotic and health food, including the active ingredient, and can be used in the form of various other food additives.
본 발명의 실시예들에 따른 조성물은 건강 식품용 조성물일 수 있다.The composition according to the embodiments of the present invention may be a composition for health food.
본 발명의 실시예에 따른 건강식품용 조성물은 상기 유효성분을 조성물 총 중량에 대하여 0.0001중량% 내지 99중량%, 예를 들어 0.01 중량% 내지 60중량%로 포함할 수 있으나, 이에 제한되지 않는다.The health food composition according to the embodiment of the present invention may include 0.0001% by weight to 99% by weight, for example, 0.01% by weight to 60% by weight, based on the total weight of the composition, but is not limited thereto.
구체예에서, 상기 건강 식품용 조성물은 환제, 캅셀제, 정제, 과립제, 캬라멜제 또는 드링크제 등으로 제형화할 수 있다. 다른 구체예에서, 액제, 분말, 과립, 정제 또는 티백 등의 형태로 가공될 수도 있다. In embodiments, the health food composition may be formulated as pills, capsules, tablets, granules, caramels or drinks. In other embodiments, it may be processed in the form of a liquid, powder, granules, tablets or tea bags and the like.
상기 조성물은 단순 음용, 주사 투여, 스프레이 방식 또는 스퀴즈 방식 등의 다양한 방법으로 투여될 수 있다.The composition may be administered by various methods, such as simple drinking, injection, spray or squeeze.
상기 조성물은 본 발명의 주 효과를 손상시키지 않는 범위 내에서 주 효과에 상승 효과를 줄 수 있는 다른 성분 등을 함유할 수 있다. 예를 들어, 물성 개선을 위하여 향료, 색소, 살균제, 산화방지제, 방부제, 보습제, 점증제, 무기염류, 유화제 및 합성 고분자 물질 등의 첨가제를 더 포함할 수 있다. 그 외에도, 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당 및 해초 엑기스 등의 보조 성분을 더 포함할 수도 있다. 상기 성분들은 제형 또는 사용 목적에 따라서 당업자가 적의 선정하여 배합할 수 있으며, 그 첨가량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. 예를 들어, 상기 성분들의 첨가량은, 조성물 전체 중량을 기준으로, 0.01중량% 내지 5 중량%, 예를 들어 0.01중량% 내지 3중량% 일 수 있으나, 이에 제한되는 것은 아니다.The composition may contain other ingredients and the like that can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention. For example, it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties. In addition, supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included. The above ingredients may be suitably selected and formulated by those skilled in the art according to the dosage form or purpose of use, and the amount thereof may be selected within a range that does not impair the object and effect of the present invention. For example, the amount of the components added may be 0.01 wt% to 5 wt%, for example, 0.01 wt% to 3 wt%, based on the total weight of the composition, but is not limited thereto.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as limited by these examples.
[[ 시험예Test Example 1] 글루코코르티코이드 유도성 세포 사멸 억제 효과 1] Glucocorticoid-induced cell death inhibitory effect
마그놀롤의 항스트레스 효과 확인을 위하여 글루코코르티코이드로 유도한 세포 사멸에 대한 실험을 수행하였다.In order to confirm the antistress effect of magnolol, an experiment on glucocorticoid-induced cell death was performed.
PC12 (신경세포종 세포; KCLB21721, 한국세포주은행)를 96 well plate에 2*104 cell/well씩 접종하여 5% CO2, 37℃ 조건에서 배양하였다. 배양 배지는 10% 혈청(heat-inactivated fetal bovine serum (FBS, Gibco)), 100 U/ml 페니실린(penicillin (Gibco)) 및 100 μg/ml 스트렙토마이신(streptomycin(Gibco))이 첨가된RPMI 1640 (Gibco BRL, Grand Island, NY, USA)) 배지를 사용하였다. 여기에 스트레스 호르몬인 코르티코스테론(corticosterone, sigma, MA) 400 μM 을 처리하여 5% CO2, 37℃ 조건에서 24시간 동안 배양하여 스트레스를 유도하였다. 양성 대조군으로는 코르티코스테론400μM 과 항우울제인 플루옥세틴(fluoxetine hydrochloride, Sigma) 50 μM 를 사용하였으며, 마그놀롤 처리군은 코르티코스테론 400μM과 마그놀롤(magnolol, sigma, MA) 50μM를 사용하였다. 플루옥세틴과 마그놀롤은 코르티코스테론 처리 2시간전에 각각 전처리 하였다. 상기 각 well마다 CCK-8 solution (Dojindo Laboratories) 을 10㎕ 씩 첨가하고 2시간 배양한 다음 540nm에서 측정하였다. 측정된 결과에서 코르티코스테론 무처리군의 값을 1로 하여 상대적인 세포 증식율을 도 1에 나타내었다.PC12 (neurocytoma cell; KCLB21721, Korea Cell Line Bank) was inoculated at 2 * 10 4 cell / well in 96 well plate and incubated at 5% CO 2 , 37 ° C. Culture medium was prepared using RPMI 1640 (10% serum (FBS, Gibco), 100 U / ml penicillin (Gibco) and 100 μg / ml streptomycin (Gibco). Gibco BRL, Grand Island, NY, USA)) media. The stress hormone corticosterone (corticosterone, sigma, MA) was treated with 400 μM incubated at 5% CO 2 , 37 ℃ condition for 24 hours to induce stress. As a positive control, 400 μM of corticosterone and 50 μM of anti-depressant fluoxetine hydrochloride (Sigma) were used, and 400 μM of corticosteroid and 50 μM of magnolol (magnolol, sigma, MA) were used for the magnolol treatment group. Fluoxetine and magnolol were pretreated 2 hours prior to corticosteroid treatment, respectively. For each well, 10 μl of CCK-8 solution (Dojindo Laboratories) was added, incubated for 2 hours, and measured at 540 nm. In the measured results, relative cell proliferation was shown in FIG.
도 1의 결과에서, 마그놀롤은 대표적인 스트레스 관련 글루코코르티코이드계 호르몬인 코르티코스테론 유도성 세포 사멸을 억제하는 효과가 우수한 점을 확인할 수 있다.In the results of FIG. 1, it can be seen that magnolol has an excellent effect of inhibiting corticosteroid induced cell death, a typical stress-related glucocorticoid hormone.
[제형예 1] 정제 Formulation Example 1 Tablet
본 발명 제조예 1의 용출물 100mg, 락토오스 400mg, 옥수수 전분 400mg 및 스테아린산 마그네슘 2mg을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.100 mg of the eluate of Preparation Example 1 of the present invention, 400 mg of lactose, 400 mg of corn starch, and 2 mg of magnesium stearate were mixed, followed by tableting according to a conventional method for preparing tablets.
[제형예 2] 캡슐제 Formulation Example 2 Capsule
본 발명 제조예 1의 용출물 100mg, 락토오스 400mg, 옥수수 전분 400mg 및 스테아린산 마그네슘 2mg을 혼합한 후, 통상의 캡슐제의 제조 방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.100 mg of the eluate of Preparation Example 1 of the present invention, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate were mixed, followed by filling into a gelatin capsule according to a conventional capsule preparation method to prepare a capsule.
[제형예 3] 과립제Formulation Example 3 Granules
본 발명 제조예 1의 용출물 50mg, 무수결정 포도당 250mg 및 전분 550mg을 혼합하고, 유동층 과립기를 사용하여 과립으로 성형한 후 포에 충진하였다.50 mg of the eluate of Preparation Example 1 of the present invention, 250 mg of anhydrous glucose and 550 mg of starch were mixed, molded into granules using a fluidized bed granulator, and then filled into fabrics.
[제형예 4] 드링크제[Formulation Example 4] Drinks
본 발명 제조예 1의 용출물 50mg, 포도당 10g, 구연산 0.6g, 및 액상 올리고당 25g을 혼합한 후 정제수 300ml를 가하여 각 병에 200ml씩 충진한다. 병에 충진한 후 130℃ 에서 4~5 초간 살균하여 드링크제를 제조하였다.50 mg of the eluate of Preparation Example 1 of the present invention, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharides were mixed, and 300 ml of purified water was added thereto, and 200 ml were filled in each bottle. After filling the bottle sterilized for 4-5 seconds at 130 ℃ to prepare a drink.
[제형예 5] 유연화장수(스킨로션) Formulation Example 5 Flexible Cosmetic (Skin Lotion)
하기 표에 기재된 조성에 따라 통상적인 방법으로 유연화장수를 제조하였다.According to the composition shown in the following table was prepared in the conventional method for the flexible cosmetic.
배합 성분Compounding ingredient 함량 (중량%)Content (% by weight)
마그놀롤Magnolol 0.20.2
글리세린glycerin 3.03.0
부틸렌글리콜Butylene glycol 2.02.0
프로필렌글리콜Propylene glycol 2.02.0
카르복시비닐폴리머Carboxy Vinyl Polymer 0.10.1
피이지-12 노닐페닐에테르Fiji-12 nonylphenyl ether 0.20.2
폴리솔베이트 80Polysorbate 80 0.40.4
에탄올ethanol 10.010.0
트리에탄올아민Triethanolamine 0.10.1
방부제, 색소, 향료Preservative, coloring, flavoring 적량Quantity
정제수Purified water 잔량Remaining amount
[제형예 6] 영양화장수(밀크로션)Formulation Example 6 Nutritious Longevity (Milk Lotion)
하기 표에 기재된 조성에 따라 통상적인 방법으로 영양화장수를 제조하였다.Nutrients were prepared in a conventional manner according to the composition shown in the table below.
배합 성분Compounding ingredient 함량 (중량%)Content (% by weight)
마그놀롤Magnolol 1.01.0
글리세린glycerin 3.03.0
부틸렌글리콜Butylene glycol 3.03.0
프로필렌글리콜Propylene glycol 3.03.0
카르복시비닐폴리머Carboxy Vinyl Polymer 0.10.1
밀납Beeswax 4.04.0
폴리솔베이트 60Polysorbate 60 1.51.5
카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 5.05.0
스쿠알란Squalane 5.05.0
솔비타세스퀴올레이트Sorbitassquioleate 1.51.5
유동파라핀Liquid paraffin 0.50.5
세테아릴 알코올Cetearyl Alcohol 1.01.0
트리에탄올아민Triethanolamine 0.20.2
방부제, 색소, 향료Preservative, coloring, flavoring 적량Quantity
정제수Purified water 잔량Remaining amount
[제형예 7] 마사지 크림Formulation Example 7 Massage Cream
하기 표에 기재된 조성에 따라 통상적인 방법으로 마사지 크림을 제조하였다.Massage cream was prepared in a conventional manner according to the composition described in the table below.
배합 성분Compounding ingredient 함량(중량%)Content (% by weight)
마그놀롤Magnolol 2.02.0
글리세린glycerin 8.08.0
부틸렌글리콜Butylene glycol 4.04.0
유동파라핀Liquid paraffin 45.045.0
베타글루칸Beta Glucan 7.07.0
카보머Carbomer 0.10.1
카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 3.03.0
밀납Beeswax 4.04.0
세테아릴 글루코사이드Cetearyl Glucoside 1.51.5
세스퀴 올레인산 소르비탄Sesqui oleic acid sorbitan 0.90.9
바세린Vaseline 3.03.0
파라핀paraffin 1.51.5
방부제, 색소, 향료Preservative, coloring, flavoring 적량Quantity
정제수Purified water 잔량Remaining amount
[제형예 8] 헤어 로션의 제조Formulation Example 8 Preparation of Hair Lotion
아래 표에 기재된 조성으로 통상의 방법에 따라 헤어 로션을 제조한다.A hair lotion is prepared according to a conventional method with the composition described in the table below.
성분ingredient 함량(중량%)Content (% by weight)
마그놀롤Magnolol 2.02.0
정제수Purified water 잔량Remaining amount
글리세린glycerin 3.03.0
부틸렌그리콜Butylene glycol 3.03.0
유동파라핀Liquid paraffin 7.07.0
베타글루칸Beta Glucan 7.07.0
카보머Carbomer 0.10.1
에델바이스 추출물Edelweiss extract 2.02.0
카프릴릭 카프릭 트리글리세라이드Caprylic Capric Triglycerides 3.03.0
스쿠알렌Squalene 5.05.0
세테아릴 그루코사이드Cetearyl Glucoside 1.51.5
소르비탄 스테아레이트Sorbitan stearate 0.40.4
폴리솔베이트Polysorbate 1.21.2
방부제antiseptic 적량Quantity
향incense 적량Quantity
색소Pigment 적량Quantity
트리에탄올 아민Triethanol amine 0.10.1
[제형예 9] 샴푸 조성물의 제조Formulation Example 9 Preparation of Shampoo Composition
아래 표에 기재된 조성으로 통상의 방법에 따라 샴푸 조성물을 제조하였다.A shampoo composition was prepared according to a conventional method with the compositions described in the table below.
성분(중량%)Ingredient (% by weight) 함량(중량%)Content (% by weight)
폴리쿼터늄-10Polyquaternium-10 0.50.5
소듐라우레스설페이트Sodium laureth sulfate 2020
마그놀롤Magnolol 0.30.3
향incense 1.01.0
메틸파라벤Methylparaben 0.10.1
세틸알콜Cetyl alcohol 0.50.5
염화나트륨Sodium chloride 0.80.8
정제수Purified water To 100To 100
[제형예 10] 헤어 트리트먼트의 제조Formulation Example 10 Preparation of Hair Treatment
아래 표에 기재된 조성으로 통상의 방법에 따라 헤어 트리트먼트를 제조하였다.Hair treatments were prepared according to conventional methods with the compositions described in the table below.
구분(중량%)Division (weight%) 함량(중량%)Content (% by weight)
마그놀롤Magnolol 0.50.5
스테아라미도프로필디메틸아민Stearamidopropyldimethylamine 22
글리세린glycerin 0.50.5
향료Spices 0.50.5
방부제antiseptic 0.030.03
세토스테아릴알코올Cetostearyl alcohol 55
락트산Lactic acid 1One
증류수Distilled water to 100to 100

Claims (10)

  1. 마그놀롤(magnolol), 이의 약학적 또는 화장품학적으로 허용 가능한 염, 이의 수화물 또는 이의 용매화물을 유효성분으로 포함하는 항스트레스 조성물.An antistress composition comprising magnolol, a pharmaceutically or cosmetically acceptable salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
  2. 제1항에 있어서,The method of claim 1,
    상기 마그놀롤은 하기 화학식으로 표시되는 구조를 가지는 화합물인, 조성물.The magnolol is a compound having a structure represented by the following formula.
    <화학식><Formula>
    Figure PCTKR2017010388-appb-I000002
    Figure PCTKR2017010388-appb-I000002
  3. 제1항에 있어서,The method of claim 1,
    상기 조성물은 글루코코르티코이드(glucocorticoid)계 호르몬 유도성 스트레스에 저항성을 나타내는, 조성물.The composition is resistant to glucocorticoid-based hormone-induced stress, the composition.
  4. 제3항에 있어서,The method of claim 3,
    상기 글루코코르티코이드계 호르몬은 코티솔(cortisol), 코티손(cortisone) 및 코르티코스테론(corticosterone) 중에서 선택되는 1종 이상을 포함하는, 조성물.The glucocorticoid-based hormone comprises at least one selected from cortisol, cortisone and corticosterone.
  5. 제1항에 있어서,The method of claim 1,
    상기 조성물은 스트레스로 유발되는 신체 증상을 완화 또는 개선시키는, 조성물.Wherein said composition alleviates or ameliorates physical symptoms caused by stress.
  6. 제1항에 있어서,The method of claim 1,
    상기 조성물은 스트레스로 유발되는 심리적 증상을 완화 또는 개선시키는, 조성물The composition may alleviate or ameliorate psychological symptoms caused by stress.
  7. 제1항에 있어서,The method of claim 1,
    상기 조성물은 화장료용인, 조성물.The composition is a cosmetic composition.
  8. 제7항에 있어서,The method of claim 7, wherein
    상기 유효성분은 조성물 총 중량에 대하여 0.01 중량% 내지 99 중량%로 포함되는, 조성물.The active ingredient is contained in an amount of 0.01% to 99% by weight based on the total weight of the composition.
  9. 제1항에 있어서,The method of claim 1,
    상기 조성물은 건강식품용인, 조성물.The composition is for health food, the composition.
  10. 제9항에 있어서,The method of claim 9,
    상기 유효성분은 조성물 총 중량에 대하여 0.01 중량% 내지 99중량%로 포함되는, 조성물. The active ingredient is contained in an amount of 0.01% to 99% by weight based on the total weight of the composition.
PCT/KR2017/010388 2016-09-27 2017-09-21 Anti-stress composition containing magnolol WO2018062765A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0124255 2016-09-27
KR1020160124255A KR20180034126A (en) 2016-09-27 2016-09-27 Anti-stress composition comprising magnolol

Publications (1)

Publication Number Publication Date
WO2018062765A1 true WO2018062765A1 (en) 2018-04-05

Family

ID=61760801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/010388 WO2018062765A1 (en) 2016-09-27 2017-09-21 Anti-stress composition containing magnolol

Country Status (2)

Country Link
KR (1) KR20180034126A (en)
WO (1) WO2018062765A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111202064A (en) * 2020-02-28 2020-05-29 北京农业质量标准与检测技术研究中心 Application of magnolol in inhibiting alternaria from synthesizing mycotoxin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HSU, C.-C.: "Honokiol protected against heatstroke-induced oxidative stress and inflammation in diabetic rats", INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, vol. 2014, 134575, 17 February 2014 (2014-02-17), pages 1 - 10, XP055603098, ISSN: 1687-8337, DOI: 10.1155/2014/134575 *
SONG, X.: "Traditional Chinese medicine prescriptions enhance growth performance of heat stressed beef cattle by relieving heat stress responses and increasing apparent nutrient digestibility", ASIAN AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES, vol. 27, no. 10, 1 October 2014 (2014-10-01), pages 1513 - 1520, XP055603081, ISSN: 1011-2367, DOI: 10.5713/ajas.2014.14058 *
SULAKHIYA, K.: "Honokiol abrogates lipopolysaccharide-induced depressive like behavior by impeding neuroinflammation and oxido-nitrosative stress in mice", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 744, 5 December 2014 (2014-12-05), pages 124 - 131, XP055603093, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2014.09.049 *
TALBOTT, S. M. ET AL: "Effect of Magnolia officinalis and Phellodendronamurense (Relora) on cortisol and psychological mood state in moderately stressed subjects", JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION, vol. 10, no. 37, 2013, pages 1 - 6, XP021160313, ISSN: 1550-2783, DOI: 10.1186/1550-2783-10-37 *
XU, Q.ET AL: "Antidepressant like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 32, no. 3, 1 January 2008 (2008-01-01), pages 715 - 725, XP022508052, ISSN: 0278-5846, DOI: 10.1016/j.pnpbp.2007.11.020 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111202064A (en) * 2020-02-28 2020-05-29 北京农业质量标准与检测技术研究中心 Application of magnolol in inhibiting alternaria from synthesizing mycotoxin
CN111202064B (en) * 2020-02-28 2021-09-03 北京农业质量标准与检测技术研究中心 Application of magnolol in inhibiting alternaria from synthesizing mycotoxin

Also Published As

Publication number Publication date
KR20180034126A (en) 2018-04-04

Similar Documents

Publication Publication Date Title
EP3581192B1 (en) Composition for enhancing immunity, containing ginseng berry polysaccharides
KR102610933B1 (en) Composition for hair or scalp comprising lysate of Lactobacillus plantarum
JP2006257064A (en) Lipid absorption-suppressing composition
WO2015002393A1 (en) Composition for treating or preventing inflammatory skin disease, comprising, as active ingredient, immature citrus fruit extract, or synephrine or salt thereof
KR20200050068A (en) Composition Comprising the 3,5-Dicaffeoylquinic Acid for Recovery of Distrupted Skin Barrier and/or Alleviating Skin Inflammation
WO2017014502A1 (en) Pharmaceutical composition for preventing or treating il-6-mediated diseases comprising rosa rugosa flower extract as active ingredient
WO2018062801A1 (en) Anti-stress composition containing cosmoperine
WO2018203668A1 (en) External-use skin preparation composition for alleviating atopic skin, and cosmetic containing same
KR101248503B1 (en) Composition for improving atopic dermatitis comprising hot water extract of green tea and ethanol extract of green tea
TW201116286A (en) Ceramide production enhancer and moisturizing agent
WO2020096127A1 (en) Composition comprising hydrolyzed sponge for relieving arthralgia or myalgia
WO2018062765A1 (en) Anti-stress composition containing magnolol
WO2018062800A1 (en) Anti-stress composition containing esculin
WO2018062764A1 (en) Anti-stress composition containing honokiol
WO2020091295A1 (en) Composition comprising ailanthus altissima bark extract as active ingredient for caring for acne skin or inhibiting sebum secretion
WO2023042959A1 (en) Anti-inflammatory composition comprising complex ginsenoside composition
KR101273027B1 (en) Composition for inhibiting sebum secretion and anti-obesity comprising kaempferol
KR101906896B1 (en) Composition Comprising Thymol and Myrcene for Preventing or Treating in Atopic Dermatitis as Active Ingredient
KR102137144B1 (en) Composition for anti-inflammation comprising leaf extracts of pyracantha angustifolia
KR100485936B1 (en) Anticarcinogenic constituents of ginsenoside Rh2 and Rg3
JP5542145B2 (en) Antibacterial pharmaceutical composition comprising an extract of rockhopper and an active ingredient separated therefrom
WO2019151585A1 (en) Composition for skin whitening comprising 5-iodotubercidin as active ingredient
WO2022092495A1 (en) Composition for prevention, amelioration, or treatment of hypersensitivity immune disease containing galactose
WO2010128788A2 (en) Anti-obesity external dermal agent compositions containing capsaicin or capsaicin-like compounds as active ingredients
WO2018016783A1 (en) Moisturizing composition containing 3-o-galloyl-3,3&#39;,5,5&#39;,7-pentahydroxyflavan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17856651

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17856651

Country of ref document: EP

Kind code of ref document: A1